PRLD Earnings Date: Nov 11, 2026 (Estimated) — Prelude Therapeutics Incorporated
NASDAQ · Healthcare · Biotechnology
Updated
When is PRLD's next earnings date?
Prelude Therapeutics Incorporated (PRLD) is expected to report Q3 2026 earnings on Wednesday, November 11, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.00 on revenue of $29.0M.
How did PRLD do in its last earnings report?
In its most recent report on Aug 11, 2026 (Q2 2026), Prelude Therapeutics Incorporated posted EPS of -$0.14 versus the -$0.20 estimate, a beat of 22.2%. Revenue was $5.7M against a $5.7M estimate. The stock's 1-day post-earnings move was +10.1%.
How much does PRLD stock move after earnings?
PRLD beat EPS estimates in 7 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 6.9% (up or down) in the day after earnings.
About Prelude Therapeutics Incorporated
Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies. Another asset, PRT811, is also in Phase 1 trials, targeting various solid tumors, notably glioblastoma multiforme. The company is additionally progressing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a powerful and highly kinome-selective CDK9 inhibitor; PRT-SCA2, which is in preclinical development for several genomically selected cancers; PRT3645, a brain-penetrant molecule that precisely and effectively targets CDK4/6; and PRT-K4, another preclinical compound for solid tumors. Founded in 2016, the firm's headquarters are located in Wilmington, Delaware.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-11 | Q2 2026 | -0.20 | -0.14 | +22.22% | $5.7M | ✅ Beat | +10.14% | +16.56% | +5.38% |
| 2026-05-12 | Q1 2026 | -0.27 | -0.13 | +51.85% | $4.6M | ✅ Beat | -3.33% | -9.58% | -17.71% |
| 2026-03-10 | Q4 2025 | -0.24 | -0.20 | +16.67% | $5.6M | ✅ Beat | +16.50% | +8.74% | +36.57% |
| 2025-11-12 | Q3 2025 | -0.35 | -0.26 | +25.71% | $6.5M | ✅ Beat | +8.89% | +24.44% | +20.74% |
| 2025-08-14 | Q2 2025 | -0.44 | -0.41 | +6.82% | $0 | ✅ Beat | +4.19% | +15.77% | +24.59% |
| 2025-03-10 | Q4 2024 | -0.47 | -0.37 | +21.28% | $4.0M | ✅ Beat | -1.34% | +12.67% | -8.88% |
| 2024-11-06 | Q3 2024 | -0.47 | -0.43 | +8.51% | $3.0M | ✅ Beat | -3.79% | -19.70% | -27.71% |
| 2024-08-12 | Q2 2024 | -0.42 | -0.46 | -9.52% | $0 | ❌ Miss | -6.86% | +2.16% | +5.49% |
Showing last 8 quarters.